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Abstract
Background: Evidence-based outpatient psychotherapeutic programs are first-line treatment of borderline personality
disorder (BPD). Early and effective treatment of BPD is crucial to the prevention of its individual, psychosocial, and
economic consequences. However, in spite of recent advantages in diagnosing adolescent BPD, there is a lack of
cost-effective evidence-based treatment programs for adolescents. Mentalization-based treatment is an evidence-based
program for BPD, originally developed for adults.
Methods/Design: Aims/hypotheses: We will investigate whether a specifically designed mentalization-based treatment
in groups is an efficacious treatment for adolescents with BPD or subthreshold BPD compared to treatment as usual.
The trial is a four-center, two-armed, parallel-group, assessor-blinded randomized clinical superiority trial. One hundred
twelve patients aged 14 to 17 referred to Child and Adolescent Psychiatric Clinics in Region Zealand are randomized to
1 year of either mentalization-based treatment in groups or treatment as usual. Patients will be included if they meet at
least four DSM-5 criteria for BPD. The primary outcome is self-reported borderline features at discharge. Secondary
outcomes will include self-harm, depression, BPD criteria, externalizing and internalizing symptoms, and social
functioning, together with parental reports on borderline features, externalizing and internalizing symptoms. Measures of
attachment and mentalization will be included as mediational variables. Follow-up assessment will take place at 3 and
12 months after end of treatment.
Discussion: This is the first randomized controlled trial to test the efficacy of a group-based mentalization-based
treatment for adolescents with BPD or subthreshold BPD. If the results confirm our hypothesis, this trial will add
to the treatment options of cost-effective treatment of adolescent BPD.
Trial registration: Clinicaltrials.gov NCT02068326, February 19, 2014.
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Background
Borderline personality disorder (BPD) is a severe mental
disorder with symptoms such as affective instability, impul-
sivity and self-harm [1]. In comparison to other personality
disorders (PDs), BPD is associated with more severe impair-
ments in social functioning [2, 3], higher rates of psychiatric
comorbidity and increased risk of suicide attempts [4].
Prevalence in the general population ranges from 0.5 to
2.7 % [5–9]. In clinical populations the prevalence ranges
between 9 and 22 % in outpatient settings [10, 11], and up
to 40 % in inpatient settings [12]. Research into the etiology
of BPD indicates that it is multifactorial and includes gen-
etic dispositions, neuropsychological dysfunctions, and en-
vironmental factors such as neglect and physical abuse [13].
It has been disputed whether it is possible and mean-
ingful to diagnose PDs in general and BPD in particular
in adolescents [14–16]. However, there is evidence that
BPD can be diagnosed reliably and validly in adolescents
with reliability rates comparable to those found with
adults [17–22]. The possibility of diagnosing adolescent
PD has been introduced in the Diagnostic and Statistical
Manual of Mental Disorders, fifth edition (DSM-5) [1]
and BPD prevalence rates among adolescent inpatients
are similar to those of adult inpatients [23, 24]. Stability
of PD diagnoses among adolescents also resembles that
of adults [25].
BPD is associated with both chronic medical illnesses
and comorbid psychiatric disorders, and psychiatric co-
morbidity may be even higher in adolescents than in
adults [26–31]. Patients with BPD tend to use inpatient
and outpatient treatment far more than patients with
other PDs [32] leading BPD to be associated with costly
health service use [27, 33], also in adolescence [34, 35].
Therefore, the development of early and effective treat-
ment programs, which include adolescents with BPD at
the threshold level is important and may have long-term
benefits for patients, their families and society [36–40].
While pharmacological treatments can reduce specific
symptoms experienced by BPD patients, they fail to
bring about a fundamental or long-lasting change in the
disorder itself. In contrast, several structured outpatient
psychotherapeutic programs such as dialectical behavior
therapy (DBT), mentalization-based treatment (MBT),
transference-focused therapy (TFP), cognitive behavioral
therapy (CBT) and schema-focused group therapy (SFT)
have been shown to be efficacious. Although further evi-
dence is still warranted, psychotherapy is suggested as
the primary treatment for BPD [41, 42].
Adaptation of structured and manualized treatment
programs to adolescents with BPD is novel, and relatively
few controlled studies have tested their efficacy: In an ran-
domized controlled trial (RCT) by Mehlum et al., DBT-A
was found to be superior to the control condition in redu-
cing the frequency of self-harm, both at treatment end
and at follow-up [43, 44]. Other studies on feasibility and
efficacy of DBT-A also indicate a positive outcome for
DBT-A [45–49], but these studies are uncontrolled, small
scale, and use different outcome measures, leading the
evidence base to be considered insufficient [50]. As the
target population for DBT-A is adolescents with suicidal
and self-harming behavior, the overlap between this
group and adolescents with BPD is only partial [50],
and the efficacy of DBT-A for treating BPD in adoles-
cents is unknown. Chanen et al. [51] tested individual
cognitive analytic therapy (CAT) for adolescents with
BPD symptoms and found no significant differences be-
tween the outcomes of CAT and the control condition
at 24 months, but with faster rates of symptomatic im-
provement in the CAT condition. Schuppert et al. [52]
also found no superiority of a 17-session group-based
emotion regulation training course. In contrast, Rossouw
and Fonagy’s [53] adaptation of mentalization-based treat-
ment (MBT) for borderline personality patients to adoles-
cents yielded more promising results: A 1-year treatment
program for adolescents with self-harming behavior (of
whom 73 % met the diagnostic criteria for BPD) compris-
ing weekly individual MBT sessions and monthly family-
therapy sessions, was more effective than treatment as
usual (TAU). In an uncontrolled study, Laurenssen et al.
[54] adapted MBT to an inpatient setting with adolescent
BPD patients, and found a significant improvement in
Axis-I symptomatology and personality functioning.
MBT is specifically developed to treat BPD and its effi-
cacy of treating BPD in adults has been tested in several
RCTs [55–58]. MBT is based on attachment theory and
psychodynamic principles and has a high degree of struc-
ture and a clear treatment goal of improving patients’
mentalizing skills [55–59]. Mentalization has been defined
as the capacity to understand and interpret - implicitly
and explicitly - one’s own and others’ behavior as an
expression of mental states such as feelings, thoughts, fan-
tasies, beliefs, and desires [60]. The capacity develops dur-
ing childhood and is intimately linked with the quality of
early attachment relationships [61]. When the caregivers
affective mirroring of the child’s mental state is marked
and congruent, i.e., is representative of the child’s mental
state, and not her own, it serves as a representation of the
state that the child can incorporate into its own represen-
tation of self [60]. The theoretical framework of MBT
links BPD pathology to an impairment in the capacity to
mentalize. In states of emotional arousal, BPD patients are
vulnerable to shifting toward a non-mentalizing mode. In
short, MBT offers therapeutic techniques for identifying
when this shift is occurring and how to help the patient
return to a mentalizing mode, where an understanding of
one’s own and others’ minds can be used to regulate the
patient’s emotional state [40]. In the original model for
MBT, group psychotherapy is supported by individual
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psychotherapy that ensures patients’ attendance to group
sessions by motivating and working constructively with
patients’ negative experiences that could otherwise lead
them to drop out of treatment [59]. However, such a rela-
tively resource-demanding treatment model can impede
implementation, and research into the effectiveness of the
separate modalities of MBT is sparse.
While the overall aim of developing patients’ mentaliz-
ing skills overlaps in individual and group therapy, there
may be some particular advantages to using the group
modality in the treatment of BPD. Karterud [62] summa-
rizes the literature on these advantages as follows: First,
the relatively intimate two-person relationship of indi-
vidual therapy is likely to activate attachment patterns
and transference/countertransference that are emotion-
ally too burdening for the BPD patient to endure. In the
group, such interpersonal processes will be “spread out”
on different group members and therefore be experi-
enced as less intense. Second, as the interpersonal diffi-
culties associated with BPD naturally unfold between
group members, group therapy offers an opportunity to
explore and work on them in vivo. Third, difficulty with
authority figures experienced by many BPD patients can
diminish their receptiveness to feedback coming from
the therapist. In contrast, when feedback comes from
group members, this difficulty may be bypassed. Further-
more, compared to individual therapy, group therapy is
considerably less expensive.
Including parents in the MBT program for adolescent
BPD and targeting the parent-child relationship is im-
portant. Parental and family circumstances are contrib-
uting factors to the development of BPD [63, 64], and
BPD symptoms such as affect dysregulation and impul-
sivity are especially prone to be exhibited within the
context of attachment relationships [40], such as the re-
lationship between adolescents with BPD and their par-
ents. We suggest that guidance for parents on how to
understand and respond to their child in interpersonal
stressful situations can promote mentalization and co-
regulation within the parent-adolescent relationship, and
that these intersubjective experiences may serve as a
pathway to development of the adolescents’ mentalizing
skills. We also propose that it will reduce premature
dropout to educate and guide the parents about the im-
portance of supporting their child in times of low motiv-
ation for attending treatment sessions [65].
To our knowledge, group-based MBT for adolescent
BPD or subthreshold BPD that includes parents in the
treatment has not yet been tested for efficacy in a con-
trolled study. However, in an uncontrolled feasibility trial
(N = 25) of a group-based MBT program similar to the
one presented in the present protocol, we found symp-
tomatic improvement in 92 % of the patients. On the Bor-
derline Personality Features Scale for Children (BPFS-C),
which is also the primary outcome measure in the
present trial, the difference in before and after scores
were highly significant (Bo, Sharp, Beck, Pedersen,
Gondan and Simonsen (submitted)).
Aims and hypotheses
We will investigate whether a specifically designed treat-
ment program, Mentalization-based treatment in groups
for adolescents with BPD or subthreshold BPD, is an
efficacious treatment compared to treatment as usual
(TAU). The MBT program includes an introduction to
mentalization (MBT-I), mentalization-based group ther-
apy (MBT-G) and mentalization-based psychoeducation
for the parents of the patients (MBT-P) [62, 66]. The
present study will test if this specifically designed group-
based MBT program is superior to TAU as measured by
a decrease in borderline personality features after the
last MBT-G session (session no. 40).
Methods/Design
The study is a randomized two-armed, parallel group,
assessor-blinded continuous outcome superiority trial,
comparing a group-based MBT program with TAU in
112 adolescents with BPD or subthreshold BPD, follow-
ing intention-to-treat (ITT) principles. The study will be
carried out at four outpatient child and adolescent psy-
chiatric clinics within The Child and Adolescent Psychi-
atric Department, Region Zealand, Denmark.
Eligibility criteria
Inclusion criteria
1. Age from 14 to 17 years
2. Meeting a minimum of four DSM-5 BPD criteria
3. Total score higher than clinical cutoff (67) on the
Borderline Personality Features Scale for Children
(BPFS-C)
4. Parents’ or parent substitutes’ commitment to
participate in the MBT-P program and to support
their child’s participation in the MBT-I and MBT-G
program
5. Written informed consent
Exclusion criteria
1. Comorbid diagnosis of pervasive developmental
disorder, learning disability (IQ < 75), anorexia,
current psychosis, diagnosis of schizophrenia or
schizotypal personality disorder and antisocial
personality disorder (DSM-5)
2. Any other mental disorder other than BPD considered
the primary diagnosis
3. Current (past 2 months) substance dependence (but
not substance abuse)
Beck et al. Trials  (2016) 17:314 Page 3 of 13
4. Current psychiatric inpatient treatment
5. Receiving any other psychotherapeutic treatment
6. Not living with parent(s) or parent’s substitute(s),
who are able to participate in the MBT-P program
7. Not fluent in Danish
Recruitment and baseline procedures
Participants from child and adolescent psychiatric in-
and outpatient clinics in Region Zealand will be screened
for eligibility as part of their psychiatric review and re-
ferred to further assessment, provided they do not meet
any exclusion criteria. A simple screening instrument
has been developed, and staff will be trained in using it
prior to recruitment. When clinicians encounter patients
who fulfil the inclusion criteria, the patients are sent to
an assessor, who will inform the patient and parents
thoroughly about participation in the M-GAB trial in-
cluding the assessment procedure. Patients are then in-
vited to two sessions of assessment for eligibility. Both
sessions last between 2 and 3 hours including breaks.
Subsequently the family is told if they are invited to par-
ticipate in the randomization, and if so, outcome mea-
sures at baseline are administered. Randomization will
take place after completion of the baseline assessment
and patients will be allocated to either the MBT in
groups or the TAU group (see below). The flowchart and
measurement points are presented in Fig. 1.
Interventions
Both treatment conditions, MBT in groups and TAU,
will be delivered at all four child and adolescent psychi-
atric clinics in Region Zealand.
Experimental intervention: MBT in groups
Mentalization-based group therapy is constituted by a set
of treatment principles. Naturally, some principles over-
laps with individual MBT (i.e., “regulating arousal” and
“keeping an affect focus”), but others are specific to the
group component (i.e., identifying and mentalizing events
in the group) [62, 67]. The patients’ profound difficulties
with interpersonal functioning and affect regulation re-
quire therapeutic techniques potent enough to counteract
the difficulties that can arise during sessions. A main
therapeutic goal is to balance the management of therapist
authority and structure of each session with the open-
minded, exploring, and curious stance in order “to create
and sustain a mentalizing discourse in the group” [62, 67].
MBT in groups is a 1-year psychotherapy program
with three components, MBT-Introduction (MBT-I),
MBT-Group (MBT-G) and MBT-Parents (MBT-P).
MBT-I is a structured 3-week introductory psychoedu-
cative program for patients covering the concepts of men-
talizing and attachment, and information about BPD.
MBT-I includes role plays and discussions of cases and
video clips in order to encourage active participation.
Furthermore, the group members will be encouraged to
participate in small homework assignments between the
sessions. MBT-I was developed by Karterud and Bateman
[66], and modified for our purpose in collaboration with
the authors.
Mentalization-based group therapy (MBT-G) consists
of 37 weekly sessions of mentalization-based psychother-
apy in groups. Sessions are not accompanied by continu-
ing individual sessions. However, case formulations are
made with patients during individual sessions with both
therapists, and this process scaffolds and supports the
therapeutic work in the group. The overall purpose of
the case formulation sessions is for therapists and patient
to develop a clear mutual understanding of the patient’s
main difficulties and psychotherapeutic focus points, which
can be drawn on during group sessions. The case formula-
tion is to be formulated within the mentalization-based
framework, applying the theoretical understandings and
principles from mentalization theory. The individual focus
in these sessions organizes thinking for therapists and pa-
tient and supports the mentalizing work in the ensuing
group sessions [62]. Three individual case formulation ses-
sions are scheduled before the initiation of the MBT-G.
The patient will also be informed which therapist is his or
her contact person, and an updated crisis plan with the
therapist’s contact details is included in the formulation.
After eight to ten group sessions and again toward the end
of the program (after 25 group sessions), a case formula-
tion session is scheduled for revising the formulation
according to the deepened knowledge and development of
the patient.
MBT-P is a psychoeducation program for the patients’
parents running parallel to MBT-I and MBT-G. It is a
slow-open six-session program comprising role plays,
plenary analysis of difficult interpersonal events between
parent and adolescent and therapists’ presentations with
information on BPD, mentalization, and attachment.
The importance of parents’ continuous support of their
adolescents’ attendance to treatment is also discussed.
All sessions have a length of 90 minutes. MBT-P is adapted
from Karterud and Bateman’s manual [66]. An overview of
the entire MBT in groups program is presented in Fig. 1.
Both MBT-P as well as the contact-person function men-
tioned above are intended to prevent premature dropout
of the treatment.
Therapists
MBT will be delivered by clinical psychologists and a
psychiatrist. Prior to starting the MBT treatment, thera-
pists will have participated in a 2-day introduction to
MBT theory and basic principles and a 5-day training
program by Professor Sigmund Karterud, who developed
the manual for MBT-G and MBT-I in collaboration with
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Anthony Bateman [62, 66]. Replacement of therapists
during the trial may be necessary, in which case at least
one therapist in each group will have finished training,
while the co-therapist is undertaking or waiting to begin
training. National specialists in MBT and adolescent
psychiatry provide 1–2 hours of supervision per month
to secure adherence to the manual. All sessions are
videotaped and 10 % are randomly selected for ratings of
adherence to the treatment manual applying the MBT-G
adherence and competence scale [62]. Therapists deliv-
ering MBT within this trial will not deliver TAU, but
may carry out non-MBT-based clinical work outside the
trial such as clinical assessments or case management
for in-patients.
Organization of MBT in groups within the four clinics
Whenever patients terminate/drop out of a MBT-G
group and new patients can be admitted into the group,
a new MBT-I group starts up. As a default, patients will
be offered MBT-I in their local clinic, but may also
choose to enter MBT-I in a different clinic in order to
participate in a larger group. MBT-I groups starting up
with less than five patients are run by one therapist.
Groups with five or more patients are delivered by two
therapists, Patients start MBT-G treatment immediately
after completion of MBT-I. The MBT-G treatment will
run in five slow-open groups across the four clinics with
a maximum of eight patients in each.
Treatment as usual
TAU is based on supportive techniques and comprises
psychoeducation, counseling and, if needed, ad hoc crisis
management with the overall aim of alleviating BPD
symptomatology. TAU is delivered by child and adoles-
cent mental health professionals with thorough experi-
ence in working with psychopathology in adolescents.
Fig. 1 Flow diagram of M-GAB study design. Consort flow diagram
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They will be psychologists, psychiatrists, social workers
or nurses employed in child and adolescent psychiatric
clinics in Region Zealand. Adherence to the supportive
approach is monitored in regular supervision, as TAU is
not manualized. For the purpose of this study, we defined
a limit for the minimum treatment by standardizing to at
least 12 individual monthly sessions. Additional contact
may vary across clinics and according to the needs of the
patient. The supervisors and staff selected to carry out the
TAU treatment and supervision have no previous MBT
training. They will not be undertaking MBT training dur-
ing the trial, nor will they deliver MBT to patients in- or
outside the trial. We will monitor and register both the
MBT and TAU patients’ contact to the health system dur-
ing the treatment period, to be able to report both quanti-
tatively and qualitatively the treatment both groups have
received.
Medication in the experimental intervention group and in
TAU
All patients will continuously be monitored for their use
of medication during the psychotherapeutic interven-
tion, and any differences between the groups will be ana-
lyzed as a possible confounder for outcome.
A protocol containing guidelines for pharmacological
treatment is provided (available on request) and medica-
tion will be registered. The protocol will follow the
national recommendations for treating mental disorders
in adolescents, and more specifically the new guidelines
released in June 2015 from the National Board of Health
for treatment of borderline personality [68]. All psychia-
trists responsible for medical treatment will be commit-
ted to this medical protocol adherence.
Assessment and instruments
Diagnostic evaluation at baseline
Baseline assessment will be carried out prior to
randomization by the first author and a research assist-
ant, both of whom are clinical psychologists. The first
author will not carry out treatment in any of the treat-
ment arms. The research assistant may deliver MBT-I to
smaller groups of patients. He or she will not deliver
TAU.
Clinical syndromes: general psychopathology will be
assessed with the Mini-International Neuropsychiatric
Interview for children and adolescents (MINI-KID 6.0)
[69], which is a structured diagnostic interview for chil-
dren aged between 6 and 17 years old based on 24
DSM-IV and ICD-10 criteria. The MINI-KID generates
reliable and valid psychiatric diagnoses for children and
adolescents [70].
Personality disorders will be assessed with the Struc-
tured Clinical Interview for DSM-IV-Axis II (SCID-II)
[71]. SCID-II assesses the presence of personality
disorders listed in the DSM-5. The SCID-II is considered
the “gold-standard” assessment instrument for personal-
ity disorders [72], and has shown good psychometric
properties [71]. All SCID-II interviews will be carried
out by the first author who is a trained and experienced
SCID-II interviewer.
Borderline personality disorder. Zanarini et al.’s [73]
Childhood Interview for DSM-IV Borderline Personality
Disorder (CI-BPD) was developed to also allow the iden-
tification of subthreshold borderline pathology in chil-
dren. The CI-BPD is a semi-structured interview in
which the interviewer asks a series of questions and sub-
sequently rates each DSM-based criterion on a score of
0 (absent), 1 (probably present) or 2 (definitely present).
The CI-BPD has excellent psychometric properties [73, 74]
and has demonstrated significant, albeit moderate, agree-
ment to clinician diagnosis at time of discharge in a sample
of inpatients (kappa = .47) and good internal consistency
with a Cronbach’s alpha of 0.82 [75]. The first author has
been trained in the CI-BPD by Zanarini in person and will




The primary outcome, the Borderline Personality Features
Scale for Children (BPFS-C) [76], is a 24-item dimensional
measure adapted from the borderline scale of the Person-
ality Assessment Inventory (PAI) [77] for use with chil-
dren and adolescents from 9 years of age. It has the same
four subscales as the PAI borderline scale: Negative Rela-
tionships, Affective Instability, Self-harm and Identity
Problems. The 24 items are rated on a 5-point Likert
scale, ranging from 1 (not at all true) to 5 (always true)
with a higher total score indicating more severe levels of
borderline personality features. Crick et al. [76] established
evidence for the construct validity and demonstrated high
internal consistency. Evidence for cross-informant con-
cordance, criterion and concurrent validity were estab-
lished by Sharp and colleagues [78]. Satisfactory construct
and criterion validity has also been found for the abbrevi-
ated 11-item version of the BPFS-C [79]. In an RCT of in-
dividual MBT for adolescents [53], the BPFS-C was found
to be sensitive to clinical change.
Secondary outcome measures
Depression will be measured with the Beck’s Depression
Inventory for Youth (BDI-Y) from Becks Youth Inven-
tories of emotional and social impairment, which have
also proven valid and reliable in Danish [80].
Self-harm will be measured using the self-report scale
on self-harm from the Risk-Taking and Self-Harm Inven-
tory for adolescents (RTSHIA) [81]. The RTSHIA is a
38-item measure adapted from the adult Self-Harm
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Inventory [82] to be suitable for use with adolescents.
The 38 items are rated on a 4-point Likert scale with
higher scores indicating a higher frequency with which
the adolescent has engaged in risk-taking or self-
harming behaviors. The RTSHIA has been shown to
have very high reliability (Cronbach’s alpha = 0.89, test–
retest reliability = 0.93) and validity.
Externalizing and internalizing symptoms are measured
by the Youth Self-Report (YSR) [83] and a corresponding
parents’ version, the Child Behavior Checklist (CBCL) [84].
One hundred twelve items are rated on a 3-point scale
with “0” for not true, “1” for somewhat or sometimes true,
or “2” for very or often true. Both the internalizing and the
externalizing scales comprise symptom scales correspond-
ing to DSM diagnoses. A total problem score is derived by
summing up all the symptom scales. The YSR and the
CBCL are established evidence-based assessment instru-
ments [85], which have also been validated and standard-
ized in a Danish sample [86, 87].
Borderline personality disorder symptoms are measured
with the Zanarini Rating Scale for Borderline Personality
Disorder (ZAN-BPD) [88], which is a semi-structured
interview with ratings from 0 (no symptoms) to 4 (severe
symptoms) on each of nine items corresponding to the
nine DSM-IV criteria for borderline personality disorder.
ZAN-BPD has been used in previous studies of pharmaco-
logical and psychological treatments for people with BPD.
It is reliable, sensitive to change, and has highly conver-
gent validity with structured clinical ratings of BPD [89].
Global assessment of functioning will be assessed with
the Children's Global Assessment Scale (C-GAS) that
has shown validity in measuring functioning in children
[90] and sufficient inter-rater reliability in a Danish
sample [91].
Parental reports. In addition to the parents’ version
of the YSR, the CBCL, described above, we will also
collect parental reports on borderline personality fea-
tures using the parents’ version of the BPFS-C, the
BPFS-P [78].
Sociodemographic information will also be collected at
baseline during assessment procedures and from medical
records.
Furthermore, reduction in the number of patients’ hos-
pital admissions and visits to the emergency room will be
used as a secondary outcome measure. All patients in-
cluded in the study will be followed in the National Health
Register, and we will extract data from the register dating
back to the date before the patients were enrolled in the
study as well.
Mediational variables
Attachment will be assessed with the Experience of Close
Relationships Inventory (ECR) [92] and with the Inventory
of Parent and Peer Attachment-Revised (IPPA-R) [93].
The ECR is a 36-item self-report questionnaire measuring
attachment in romantic relationships. It has displayed
good psychometric properties. The IPPA-R is a valid and
reliable 53-item measure of attachment in adolescence. It
comprises two scales that measure attachment to parents
and peers, respectively.
Mentalization will be assessed with the 46-item measure
Reflective Function Questionnaire for Youth (RFQ-Y) [94].
Measurement intervals
The primary and all self-report-based secondary outcomes
are measured at baseline, week 10, 20, 30, and after the 40th
and final MBT group session. Secondary outcomes based
on interviews and expert ratings (the ZAN-BPD, C-GAS)
are measured at baseline and discharge. The test-battery de-
signed for intake, including basic clinical evaluation, media-
tional and outcome measures will take an estimated time of
6 hours per patient. Table 1 lists the primary and secondary
outcomes, along with mediational measures.
We will have weekly self-report-based assessment in
relation to group sessions (40 measurements) and pa-
tients will fill out questionnaires in the beginning of each
group session. The assessment comprises a short form
of the BPFS-C, the BPFS-C-11, and the short version of
the Youth Self-Report, the BPM-Y (19 items). This is to
be able to monitor closely when in the treatment pro-
gram possible progress, and development in the patients’
psychopathology is obtained.
Table 1 Assessments administered at baseline and each follow-up point throughout the trial
Assessment points Outcome and mediational self-report measures Expert ratings and clinician-administered measures
Baseline Patient: BPFS-C, YSR, BDI-Y RTSHIA, ECR-R, IPPA-R, RFQ-Y
Parent: CBCL, BPFS-P
Patient: C-GAS, ZAN-BPD
10 weeks, 20 weeks, 30 weeks Patient: BPFS-C, YSR, BDI-Y RTSHIA, ECR-R, IPPA-R, RFQ-Y
Parent: CBCL, BPFS-P
Discharge Patient: BPFS-C, YSR, BDI-Y, RTSHIA, ECR-R, IPPA-R, RFQ-Y.
Parent: CBCL, BPFS-P
Patient: C-GAS, ZAN-BPD
BPFS-C Borderline Personality Features Scale for Children, YSR Youth Self-Report, BDI-Y Becks Depression Inventory for Youth, RTSHIA Risk-Taking and Self-Harm
Inventory for adolescents, ECR-R Experience of Close Relationships Inventory-Revised, IPPA-R Inventory of Parent and Peer Attachment–Revised, RFQ-Y Reflective
Function Questionnaire for Youth, C-GAS Children's Global Assessment Scale, ZAN-BPD Zanarini Rating Scale for Borderline Personality Disorder
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All applied instruments will be applied in Danish
translated versions. Published Danish versions exist of
the SCID-II, the CBCL, the YSR, the BDI-Y, the ECR-R
and the ZAN-BPD. The authors translated the remaining
instruments.
Deterioration
Any patient whose mental health deteriorates during
treatment will be taken care of according to official guide-
lines and treatment recommendations in the Department.
We will perform subgroup analyses of patients with an
increased score on the primary outcome at discharge (i.e.,
after the 40th session), in order to enhance our knowledge
about what characterizes patients who do not benefit or
deteriorate from treatment [95].
Sample size
Sample size is determined for the primary outcome,
namely, the total score of the BPFS-C. A 12-point differ-
ence between the two treatment groups is considered to
be clinically important. The only outcome study using
the BPFS-C to date reported a standard deviation of out-
come of 15.4 for psychotherapeutic treatment with a pa-
tient group similar to ours. With 90 % power and a two-
tailed significance level of 5 %, 72 patients would need
to be randomized to the two treatment arms. This calcu-
lation does not, however, take into account the similarity
of patients who are treated by the same therapists and
potential dropout.
Patients in the MBT group will be treated in five
groups with two therapists in each group. These are slow
open groups with six to seven patients, which will in-
clude a new patient as soon as another patient has fin-
ished treatment. Group treatments are known to cause
similarity of the outcomes within groups, which needs to
be accounted for in the sample size planning. We expect
an intraclass correlation of 0.03, and a total number of
eight patients treated in each of the groups, the design
effect is 1.24. Thus, the sample size has to be increased
by 24 % (which would be 90 patients). For simplicity, we
assume the same intraclass correlation in the control
group because the control patients are nested within
therapists even if the treatment is individual.
Intention-to-treat (ITT) analysis will be used, as it is the
recommended approach to evaluating RCTs ITT analysis
includes every subject who is randomized according to ran-
domized treatment assignment and it ignores noncompli-
ance, protocol deviations, withdrawal, and anything that
happens after randomization. Hence, ITT analysis preserves
prognostic balance produced from the original random
treatment allocation, but the treatment effect generated
from ITT analysis is generally conservative. We will recruit
20 % more patients to have powerful tests in both the ITT
as well as in the per protocol population even in the
presence of dropout. This yields a total of 112 patients to
be randomized, in a 1:1 ratio.
Randomization, methods to minimize bias, and blinding
In order to keep assessors blind to the patients’ treatment
allocation, all pretreatment assessments will be carried out
prior to randomization. Randomization to either MBT or
TAU are done online by the trial coordinator (the first
author) using a stratified block randomization procedure
with a computer-generated allocation sequence with a
varying block size kept unknown to the investigators by
Public Health and Quality Improvement Data Manage-
ment. Stratification will be according to clinic affiliation
and borderline severity, that is, scores on the BPFS-C.
More stratification variables are relevant (i.e., socioeco-
nomic status), but not possible to apply due to the small
number of participants. Patients randomized to the MBT
will initiate the individual case formulation sessions (see
Fig. 1) prior to MBT-I, and thereby will initiate the treat-
ment program immediately. Patients randomized to TAU
are allocated to a therapist and begin individual sessions
immediately.
Assessments during the treatment phase are limited to
self-report measures, hence no blinding will be possible.
All information given to the participants before complet-
ing the self-reports will be standardized.
Regarding outcome assessments at discharge, we will
minimize bias that knowledge of treatment allocation
could cause by implementing the following strategies: (a)
outcome assessors will be blind to treatment allocation,
(b) outcome assessors and therapists will not directly
communicate with each other, and (c) patients are asked
not to reveal their treatment allocation during outcome
assessments. Furthermore, outcome assessors will be
asked to guess the patients’ treatment allocation so that
the effects of possible bias can be examined in the analysis
and all outcome assessor interviews will be recorded and a
random sample will be re-rated by independent raters. Out-
come assessors will be research assistants or clinical psy-
chologists, who have not been trained in MBT, have not
been involved in delivering treatment to participating pa-
tients, and have not carried out any intake procedures, in-
cluding baseline assessments. The statistician will perform
statistical analyses with the two intervention groups coded
as ‘A’ and ‘B’, with randomly chosen therapist identifications.
Data management and statistical approach
Data-management will be handled by Public Health and
Quality Improvement Data Management from Central
Denmark Region, Aarhus. They will provide support
with randomization, set up questionnaires electronically
and will keep the data on their secure servers. Hence,
none of the staff members involved in the study will
have access to outcome data during the treatment phase.
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All analyses will be conducted according to the ITT
principle. Characteristics of the treatment groups will
be described at baseline. Preliminary analysis will in-
vestigate the pattern of missingness at follow-up, and
multiple imputation will be used for missing values.
The primary outcome is the total score of the BPFS-
C, which is treated as a continuous, normally distrib-
uted variable. The primary efficacy hypothesis will be
tested using a multilevel two-group comparison (MBT
vs. TAU), with Group as a main effect, Therapy
Group as a random intercept (within the MBT group,
see, e.g., [96]), the prerandomization BPFS-C as a
continuous covariate and the stratification factor
clinic as categorical covariate. The test will be per-
formed at the 5 % two-tailed significance level. The
primary test for efficacy will be based on the
intention-to-treat population, with all randomized pa-
tients entering the analysis set, and multiple imput-
ation of missing values. The result will be expressed
as the covariate-adjusted difference in group averages,
along with the two-sided 95 % confidence interval.
For the secondary outcomes, similar analyses will be
used, taking into consideration the scale of the variable
(e.g., logistic regression for binary outcomes). A sensitiv-
ity analysis will be based on the per protocol set for the
available cases (without imputation). Linear regression
and logistic regression analyses will be conducted to
examine the predictive power of the different covariates
(i.e., personality pathology, mentalizing, and attachment)
on treatment efficacy and treatment completion.
We will use multiple imputations for missing values in
the primary and secondary outcomes [97]. Separate im-
putation models will be used for the two treatment groups
[98]. The imputation models will include the primary and
secondary endpoints (baseline and follow-up) as well as
the covariates of the primary statistical analysis, and ther-
apist time in hours.
The primary analysis will be based on the pragmatic
comparison of the two treatment arms and will, there-
fore, not take different amounts of therapist time within
or across groups into account. To account for possible
differences in therapist time, a sensitivity analysis will be
performed on the change scores in which the obtained
values will be divided by the actual patient-specific hours
of therapist contact.
Mediation analyses will be carried out to test for po-
tential mediating effects of both mentalizing and attach-
ment. As recommended by Hayes [99], we will conduct
structural equation analyses (SEM), using Preacher and
Hayes [100] methods for estimating indirect and direct
effects with multiple mediators. Unstable participation
in the therapy is expected. A dropout will be determined
by clinicians as ending therapy without agreement with
the therapist.
Ethical considerations and regulatory approval
There are no immediate ethical problems regarding this
trial. Research has not identified any significant adverse ef-
fects or risks from any of the compared interventions, and
we have no advance knowledge of which intervention is
most efficacious. During the trial period, any adverse event
will be reported.
The trial is approved by the Regional Ethics Commit-
tee of Zealand (no: SJ-371), and is registered at the
Danish Data Protection Agency (no: REG-55-2014).
The trial is registered under Clinical Trials.org as
NCT02068326. In accordance with the CONSORT
guidelines [101, 102], we will report positive, negative,
and neutral findings in the trial and we have completed
the SPIRIT 2013 checklist (please see Additional file 1)
and figure (please see Additional file 2).
Confidentiality
All study-related information will be stored securely at the
study site. All participant information will be stored in
locked file cabinets in areas with limited access. All data
will be identified by a coded identification number only to
maintain participant confidentiality. All records that con-
tain names of other personal identifiers such as locator
forms and informed consent forms will be stored separ-
ately from study records identified by code number.
Protocol amendments
Any modifications to the protocol, which may affect the
conduct of the study, including changes of study objec-
tives, study design, patient population, sample sizes, or
study procedures, will require a formal amendment to
the protocol. Such amendments will be registered at
https://clinicaltrials.gov/ct2/show/NCT02068326 and ap-
proved by the ethics committee.
Discussion
BPD typically emerges in adolescence and the recom-
mended primary treatment is psychotherapeutic pro-
grams. However, only recently has research begun to
investigate essential questions such as the relative effect-
iveness of separate program components and which level
of specialization versus generalist treatment is needed
for treatment of adolescent BPD to be successful [103].
The evidence base for cost-effective treatment programs
for adolescent BPD is limited.
This is the first randomized controlled trial to test the
efficacy of a MBT in groups for adolescents with BPD or
subthreshold BPD. Below, we discuss some of the poten-
tial limitations and strengths of the M-GAB trial.
The trial is subject to at least three potential limita-
tions. First, our primary outcome measure, the BPFS-C,
was selected because it reliably and validly measures
borderline personality features specifically in adolescents
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(rather than in adults) and has shown to be a sensitive
outcome measure for adolescents in a previous random-
ized trial [53]. However, although patient-reported out-
comes have obvious benefits [104], they are not observer
blinded and therefore at risk of being assessed with
some bias. In our trial, patients allocated to MBT may
be biased by their knowledge of having received a rela-
tively specific psychotherapeutic treatment and therefore
be more optimistic about their outcome. In response to
this potential limitation, we included an observer rated
measure of change in BPD symptoms, the ZAN-BPD
[88], as a secondary outcome.
Second, no standardizations for treatment of adolescent
BPD pre-existed within the child and adolescent depart-
ment, Region Zealand and for the purpose of this study,
the limit for the minimum treatment in the TAU arm was
defined as 12 monthly individual sessions. Individual treat-
ment allows therapists to focus more intensely on the
patient compared to group-based treatment and therapists
in the TAU arm may choose to deliver treatment to some
patients with a higher frequency than once a month.
However, this does not completely rule out the risk of a
dose–response effect since MBT is delivered on a
weekly basis. We defined the minimum frequency for
TAU treatment in order to minimize the possible effect
of dose–response, but as completely equal doses of
treatment in the two treatment arms is not guaranteed,
the risk is not completely ruled out. We will monitor
and register both the MBT and TAU patients’ contact
to the health system during the treatment period, to be
able to report on any differences in the treatment doses
received.
Third, the MBT therapists are trained and supervised
by engaged and specialized supervisors in a specific
treatment model. It is possible that, as the supervisors
believe in the advantages of the MBT model, this may
influence the therapist allegiance. We were aware of the
potential allegiance bias when designing the trial, but
wanted to ensure therapist adherence to treatment model.
The alternative of having less training or less specialized
supervisors increases the risk of therapists not being
adherent to the treatment model, which we considered an
even greater risk to the trial.
We would also like to emphasize at least three possible
strengths of the trial. First, we included borderline sever-
ity as a stratification variable in order to minimize the
risk of confounding our findings by an unbalanced dis-
tribution of patients with BPD at the threshold versus
subthreshold level. Second, we included outcome mea-
sures relying on different methods and sources of data
(self-report, parental reports, observer-rated interviews and
expert ratings) and covering different aspects of quality of
life such as symptomatic improvement and social function-
ing. By including multiple outcome measures, we hope to
be able to discuss outcome in broader terms. Third, in the
selection of in- and exclusion criteria we aimed for partici-
pants to be as close to patients with BPD or subthreshold
BPD typically referred to treatment at Child and Adoles-
cent Psychiatric Department, Region Zealand. For example,
patients living with foster parents or other kinds of paren-
tal substitutes and patients presenting comorbidity or sub-
stance abuse were included. Accordingly, the findings of
the trial should have a wide generalizability.
Trial status
The trial is currently in the recruitment phase. The first pa-
tient was included and randomized on 24 September 2015
and inclusion is expected to be completed in January 2017.
Additional files
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents*. (DOC 125 kb)
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